BeiGene Shares Surge 9% Amid Positive Earnings Outlook

On January 14, shares of BeiGene (ONC.NS, 06160.HK, 688235.SH) saw an increase of over 9% in both A-shares and Hong Kong stocks, primarily driven by a favorable trend in the company's performance.

In the morning, BeiGene announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 (Eastern Time), where CEO Ouyang Qiang presented the company’s recent business developments, pipeline in hematologic malignancies and solid tumors, and future plans. Notably, he mentioned that the company expects to achieve positive operating profit for the entire year of 2025, indicating that operating income will exceed the total of operating costs, sales expenses, administrative expenses, and research and development expenses.

Positive Financial Projections

BeiGene emphasized that these forecasts are preliminary assessments based on current information regarding the global economic environment, industry trends, and the company's operational status. The company did not factor in any potential significant new business developments or one-time events, which introduces a degree of uncertainty.

If successful, this would mark BeiGene’s first annual operating profit since its inception.

Founded in 2010, BeiGene went public on NASDAQ in 2016, followed by listings on the Hong Kong Stock Exchange in 2018 and the Shanghai Stock Exchange in 2021. It became the first biopharmaceutical company to be listed in the U.S., Hong Kong, and Shanghai.

Financial History and Growth

Despite being a leading innovative pharmaceutical firm, BeiGene has faced significant annual operating losses due to high R&D investments. In its inaugural year of 2016, it reported an operating loss of $1.17 billion, with R&D expenditures reaching $98.03 million. Between 2018 and 2022, R&D expenses surged from $679 million to $1.641 billion, with operating losses escalating from $706 million to $1.79 billion.

However, in 2023, while R&D costs climbed to $1.779 billion, operating losses narrowed to $1.208 billion, largely due to strong sales of its BTK inhibitor Zebutinib (百悦泽), which surpassed $1 billion in global sales for the first time.

Future Developments

For the first three quarters of 2024, BeiGene’s operating losses further reduced to $489 million, with R&D expenses at $1.411 billion. The continuous success of Zebutinib contributed significantly to this improvement, generating 4.914 billion yuan in revenue.

On December 23, 2024, BeiGene announced a change in the ticker symbol for its American Depositary Shares on NASDAQ from “BGNE” to “ONC,” effective January 2, 2025, reflecting its commitment to providing innovative oncology drugs globally.